Eli Lilly (NYSE: LLY) stock has soared a whopping 125% over the past year. And the big pharma player has become one of the heaviest-weighted shares in the S 500, joining the ranks of top tech companies like artificial intelligence (AI) chip giant Nvidia and iPhone maker . In fact, this drugmaker with double-digit revenue gains is starting to look more and more like a growth stock.

Why is Lilly so hot these days? The company is selling one of today's most sought-after products: weight loss drugs. But not just any weight loss drugs. Lilly commercializes a class of drugs known as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. And these drugs -- Mounjaro and Zepbound -- are delivering soaring revenue as they help people worldwide shed extra pounds.

That sounds terrific, but considering Lilly's gains, you may be wondering if it's now too late to get in on this high-growth pharma stock. Let's find out.

Continue reading

Source Fool.com